心力衰竭患者的临床表型具有超正常的喷射分数
Liyan Huang1, Jiayu Feng1, Mei Zhai1
1Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC), Beijing, China.
ESC heart failure
|August 13, 2024
概括
心力衰竭患者可根据其潜在原因和并发症分为三个不同的组. 这些HFsnEF亚组的死亡风险显著不同,突显了个性化治疗策略的必要性.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 医学研究 医学研究
背景情况:
- 超正常喷射分数心力衰竭 (HFsnEF) 是一种独特的临床疾病,治疗选择有限,预后不佳.
- 了解HFsnEF内部的表型多样性对于促进疾病理解和优化患者护理至关重要.
研究的目的:
- 通过无监督集群分析,在HFsnEF群体内识别不同的表型子组.
- 探索这些已识别的HFsnEF亚组的临床特征和预后影响.
主要方法:
- 分析了一组221名住院的HF患者,其左心室喷射率≥65%.
- 在主要组件 (HCPC) 上进行了无监督的等级聚类,使用了各种临床和心声学变量.
- 使用决策树建模来确定关键的区分变量,并对每个群组评估临床结果 (所有原因死亡,心血管死亡,心血管再录取).
主要成果:
- 三个不同的HFsnEF集群出现了:集群1 (膜心脏病,较大的腔室,心房动),集群2 (缺血性心脏病,老年患者,代谢性并发症) 和集群3 (高性心肌病症).
- 鉴定出HF病因和糖尿病并发症是集群分配的关键歧视因素.
- 集群1显示,与集群2和3相比,所有原因和心血管死亡率的风险显著更高,而CV再录取率在所有集群中都是相似的.
结论:
- 该研究成功地在异构的HFsnEF队列中确定了三个不同的表型群.
- 这些群体具有独特的临床形状和差异性预后,特别是在死亡风险方面.
- 这些发现强调了认识到HFsnEF异质性对于量身定制的临床管理的重要性.
更多相关视频
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
01:22Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406